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Renoprotective effect of contemporary blocking of angiotensin II
and endothelin-1 in rats with membranous nephropathy.
Background. We previously showed that chronic administration
of an angiotensin converting enzyme (ACE) inhibitor to rats with
passive Heymann nephritis (PHN), a model of membranous
nephropathy with proteinuria and increased renal synthesis of
endothelin-1 (ET-1), reduces urinary proteins and partially limits
the exaggerated ET-1 renal synthesis. Here we compared the
effect of an ETA receptor antagonist and an ACE-inhibitor given
as single therapies with a combination of the two drugs in
uninephrectomized PHN rats.
Methods. PHN was induced with a single i.v. injection of rabbit
anti-Fx1A antibody in 40 male Sprague Dawley rats. To accelerate
the onset of renal damage rats underwent uninephrectomy seven
days later and were subsequently treated until eight months with
the ETA receptor antagonist LU-135252 (50 mg/kg b.i.d. p.o.) or
the ACE-inhibitor trandolapril (1 mg/kg in the drinking water) or
the combination of the two drugs.
Results. Either LU-135252 or trandolapril given alone pre-
vented the increase in systolic blood pressure (SBP). Combined
therapy was even more effective than single drugs. While LU-
135252 and trandolapril reduced proteinuria by 23 to 25%, the
drug combination resulted in 45% lowering of urinary proteins.
Serum creatinine was significantly decreased by the combination,
but not by the single drugs. Glomerulosclerosis and tubulointer-
stitial damage were more reduced by combined therapy than by
LU-135252 or trandolapril alone.
Conclusions. These data suggest that contemporary blocking
angiotensin II (Ang II) and ET-1 in an accelerated model of PHN
had an additive renoprotective effect than single blocking Ang II
or ET-1 and would represent a therapeutic advantage for renal
disease patients who do not completely respond to ACE inhibi-
tors.
Experimental and human proteinuric glomerulopathies
fatally evolve to end-stage renal failure by a process of
progressive parenchimal damage, which may evolve inde-
pendently from the initial insult. There is ample evidence
that in these conditions drugs that limit the synthesis or the
biological activity of angiotensin II (Ang II) retard the
progression of renal damage [1–3]. One possible explana-
tion for the remarkable effect of these classes of com-
pounds on progressive nephropathies is their unique capac-
ity of reducing glomerular capillary hypertension which is
not necessarily shared by more conventional drugs [3]. In
addition, blocking Ang II reduces glomerular protein traffic
better than other antihypertensives, thus limiting the intrin-
sic renal toxicity of proteins that once filtered in abnormal
amount by the glomerulus are endocytosed by proximal
tubuli [4]. This process triggers a series of events culminat-
ing in tubular cell dysfunction whose ultimate pathogenicity
is related to the up-regulation of genes encoding vasoactive
and inflammatory mediators [5–7]. Of this complex process
ET-1 formed in excessive amount during the process of
protein reabsorption is a major player. Tubular ET-1 is
secreted toward the basolateral membrane of the cell and
in vivo accumulates into the renal interstitium [8]. There
are in vitro data showing that ET-1 is a potent stimulus to
interstitial fibroblast proliferation and extracellular matrix
synthesis [9, 10]. That locally formed ET-1 does play a role
in the process of progressive renal injury is supported by a
number of in vivo findings. Enhanced renal ET-1 synthesis
that correlates with the severity of renal damage has been
observed in many forms of progressive nephropathies in
animals or humans [11–15]. Furthermore, selective phar-
macological manipulation of the ET-1 pathway had a major
positive impact on the progression of the disease in several
models of proteinuric nephropathies [16–19].
We have recently observed that in passive Heymann
nephritis (PHN), a rat model of membranous nephropathy
characterized by proteinuria and increased renal ET-1,
chronic administration of an ACE-inhibitor partially re-
duces proteinuria and attenuates the exaggerated ET-1
1 See Editorial by Kohan, p. 646.
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renal synthesis [14]. Although ACE-inhibition is a very
powerful therapy, it is not completely effective in normal-
izing urinary proteins nor does it completely prevent the
decline of GFR and renal damage either in animal models
and, even more importantly, in patients with progressive
nephropathies. This could be due to an only partial block-
ing of locally formed Ang II by these molecules or to an
exaggerated renal synthesis of other mediators including
ET-1 that are not necessarily controlled by ACE-inhibition.
We undertook the present study with the aim to evaluate
the effect of combining an ACE-inhibitor with an endothe-
lin receptor antagonist in a model of PHN in the rat that
was not completely responsive to an ACE-inhibitor.
Our results indicated that the combined therapy had
better renoprotective properties than each drug alone. This
study opens novel therapeutic perspectives for the treat-
ment of progressive renal diseases.
METHODS
Pilot studies
A preliminary study was performed to assess the timing
of LU-135252 administration. LU-135252 [(1)-(S)-2-(4,6
dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3 diphenyl-pro-
pionic acid], the active (1) isomer of LU 127043, is a
selective, orally active, nonpeptide ETA receptor antagonist
(Knoll AG, Ludwighafen,Germany) [20]. Two groups of
male Sprague-Dawley rats (275 to 300 g; Charles River,
Calco, Italy) were orally treated for three consecutive days:
groups 1 (N 5 3) and 2 (N 5 3) received LU-135252 (50
mg/kg/day by gavage) and evaluation of systolic blood
pressure was performed 6 or 24 hours after the last
administration of the drug, respectively. An additional
group of rats (N 5 3) were used as controls. The dose of
LU-135252 was chosen on the basis of previous experi-
ments showing that 50 mg/kg/day effectively lowered blood
pressure in angiotensin II-induced hypertensive rats [20].
Animals were anesthetized with tiopenthal sodium (60
mg/kg i.p.) and a polyethylene (PE) 240 cannula was
inserted into the trachea to facilitate breathing, one PE 50
cannula was placed in the left femoral vein for bolus
injection of ET-1 and a PE 50 cannula was advanced into
the left femoral artery to measure arterial blood pressure
with a Statham pressure transducer connected to a carrier
amplifier (Battaglia Rangoni, Bologna, Italy). Rats were
allowed to equilibrate for 30 minute intervals. Increasing
doses of ET-1 (70, 140, 300 pmol) were given as a bolus
injection at 30 minute intervals. Systolic blood pressure
(SBP) was monitored thereafter. Percent changes in mean
arterial pressure induced by ET-1 were calculated from
data obtained 10 to 20 minutes after injection of the
peptide versus the initial control period.
The effectiveness of ETA blockade and timing of LU-
135252 administration were also determined in three addi-
tional groups of rats with accelerated PHN (N 5 3 each
group, 350 to 375 body wt), which two weeks after disease
induction were orally treated for three consecutive days
with 50 mg/kg once a day or 50 mg/kg b.i.d. LU-135252 or
with vehicle. Six hours after the last administration of the
drug animals were anesthetized and experiments were
performed as described above for normal rats.
Experimental design
Male Sprague-Dawley rats (Charles River) weighing 250
to 300 g at the start of the experiment were used in this
study. Animal care and treatment were conducted in con-
formity with the institutional guidelines that are in compli-
ance with national and international laws and policies
(EEC Council Directive 86/609, OJL 358, Dec 1987; NIH
Guide for the Care and Use of Laboratory Animals, NIH
Publication No. 85-23, 1985). All animals were allowed free
access to standard rat diet containing 20% protein by
weight, and tap water. PHN was induced in non-anesthe-
tized rats by a single i.v. injection of 0.4 ml/100 g body wt of
rabbit anti-Fx1A antibody. Seven days later, when protein-
uria was already present, animals were subjected to unilat-
eral nephrectomy to accelerate the onset of renal damage
(C. Zoja, unpublished observation) and divided into four
groups.
Group 1 (N 5 10). PHN rats given daily the endothelin
receptor antagonist LU-135252, 50 mg/kg b.i.d.by gavage,
from day 7 after PHN induction for eight months.
Group 2 (N 5 10). PHN rats given the ACE-inhibitor
trandolapril daily, 1 mg/kg in the drinking water, from day
7 after PHN induction for eight months.
Group 3 (N 5 10). PHN rats given LU-135252 (50 mg/kg
b.i.d.by gavage) and trandolapril (1 mg/kg in the drinking
water) daily from day 7 after PHN induction for eight
months.
Group 4 (N 5 10). PHN rats without any treatment,
followed for eight months. An additional group of normal
rats (Group 5, N 5 6) with no treatment was followed for
eight months and used as control.
The dose of trandolapril was chosen on the basis of
previous reports showing nearly 80% inhibition of ACE
activity in serum from adult spontaneously hypertensive
rats, and blood pressure and renoprotective effects in
diabetic rats [21, 22].
In all rats SBP was recorded on months 0 (baseline), 2, 4
and 8 after PHN induction. Serum creatinine levels were
measured at baseline and every two months. Twenty-four
hour urines were collected in metabolic cages on days 0 and
7 (before treatment) and on months 2, 4 and 8 for urinary
protein excretion determination. Renal biopsies were ob-
tained from ether-anesthetized animals at the end of the
study for morphological studies by light microscopy.
Systolic blood pressure
Systolic blood pressure was recorded by tail plethysmog-
raphy in conscious rats [23].
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Serum creatinine
Blood was collected from the tail vein of anesthetized
animals. Serum was obtained after whole blood clotting and
kept at 220°C until assayed. Creatinine was measured by
the alkaline picrate method [24].
Urinary protein excretion
Proteinuria was determined in 24-hour urines by the
modified Coomassie blue G dye-binding assay for proteins
with bovine serum albumin as the standard [25].
Light microscopy
Kidney fragments were fixed for six hours in Dubosq-
Brazil, dehydrated in alcohol, and embedded in paraffin.
Sections (3 mm) were stained with hematoxylin and eosin
and periodic acid-Schiff reagent (PAS stain). Sections
including superficial and juxtamedullary glomeruli were
evaluated. At least 100 glomeruli were examined for each
animal and the percentage of glomeruli presenting focal or
global sclerotic lesions was determined. Tubular (atrophy,
casts and dilation) and interstitial changes (fibrosis and
inflammation) were graded from 0 to 41 (0, no changes;
11, changes affecting less than 25% of the sample; 21,
changes affecting 25 to 50% of the sample; 31, changes
affecting 50 to 75% of the sample, 41, changes affecting 75
to 100% of the sample). All renal biopsies were analyzed by
the same pathologist, who was unaware of the nature of the
experimental groups.
Statistical analysis
Results are expressed as mean 6 SE. Data were analyzed
using the non-parametric Kruskal-Wallis test for multiple
comparisons. Differences were considered statistically sig-
nificant at a value of P , 0.05.
RESULTS
Pilot studies
When increasing doses of ET-1 (70, 140 and 300 pmol)
were infused in anesthetized normal animals, systolic blood
pressure gradually increased from 8 to 38%. Pretreatment
with LU-135252 prevented an ET-1 induced blood pressure
increase. The effect was more marked when the last
administration of the drug was given six hours before ET-1
challenge and inhibition averaged 81 to 97%. This result
prompted us to give 50 mg/kg LU-135252 twice a day.
The choice of this schedule treatment was confirmed by
the experiments performed in rats with accelerated PHN.
Actually, ET-1 (70, 140 and 300 pmol) infusion in PHN rats
given vehicle resulted in an increase in systolic blood
pressure from 4 to 27%. When rats were pretreated with
LU-135252 at the dose of 50 mg/kg once a day, the ET-1
induced blood pressure increase was prevented by 34 to
57%, while administration of the same dose of LU-135252
but twice a day gave an inhibition of 79 to 86%.
Characteristics of accelerated PHN
Animals were subjected to unilateral nephrectomy seven
days after disease induction when proteinuria was already
present. Rats developed hypertension within four months,
similarly to the two kidney model of PHN [14, 26]. Absolute
values of proteinuria increased with time and were fairly
comparable to those of the two kidney PHN rats, although
in the accelerated model, animals of course had half the
nephron number. Increased protein traffic in the remnant
kidney over the two kidney model resulted in a more severe
renal damage. Thus, at month 8, the severity of glomerular
as well as tubulointerstitial changes were similar to those
observed in the two kidney model at month 12 [14, 26].
Animals showed glomerular hypertrophy associated with a
moderate increase of mesangial matrix, glomerular capil-
lary walls were diffusely thickened; with silver stain no
spikes were detected. In more than 50% glomeruli well
defined areas of sclerosis and hyalinosis with adhesion to
Bowman capsule were observed. Tubulointerstitial changes
consisted of severe interstitial fibrosis and inflammation
associated with tubular atrophy and with the presence of
large eosinophil casts in distal tubular lumens.
Chronic study
During the chronic study a similar mortality among the
groups of PHN rats was observed, accounting for three rats
in the treated groups while only two died among the
untreated PHN rats. Food intake was comparable in all
PHN and control rats for the entire study period. The
average food intake at month 8 was: untreated PHN, 24 6
0.9; PHN 1 LU-135252, 24 6 0.4; PHN 1 trandolapril,
21 6 1; PHN 1 LU-135252 1 trandolapril, 24 6 1; control,
23 6 1 g/day. All PHN rats gained weight in a similar
manner and at the end of the study body wt values were
comparable (PHN, 579 6 16; PHN 1 LU-135252, 581 6
22; PHN 1 trandolapril, 624 6 28; PHN 1 LU-135252 1
trandolapril, 593 6 23 g). Body weights of control rats were
numerically higher than those of PHN rats, although a
statistical significance was not reached (676 6 40 g).
Systolic blood pressure
As shown in Figure 1, in untreated PHN rats SBP
significantly increased during time as compared to control
rats, with values averaging 156 6 6 mm Hg at the end of the
study (vs. control, 129 6 1 mm Hg, P , 0.01). Treatment of
PHN rats with LU-135252 maintained SBP at values that
were significantly lower than those of untreated PHN
(135 6 3 mm Hg, P , 0.05 vs. untreated PHN). Trandola-
pril given as a single therapy prevented the increase in SBP
of PHN rats with values fairly comparable to those of
control rats (125 6 3 vs. 129 6 1 mm Hg). Combined
therapy maintained SBP at values which were even numer-
ically lower than those of controls (119 6 5 mm Hg), being
much more effective (P , 0.05) than LU-135252 alone.
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Urinary protein excretion
All groups of PHN rats developed proteinuria to a
similar extent as early as seven days after induction of the
disease compared to control rats. Proteinuria values before
treatment was as follows: untreated PHN, 74 6 15; LU-
135252, 79 6 19; trandolapril, 59 6 9; LU-135252 1
trandolapril, 64 6 12; versus control, 26 6 1 mg/day. As
shown in Figure 2 in untreated PHN rats proteinuria
increased during time averaging 855 6 67 mg/day at the
end of the study. LU-135252 and trandolapril reduced
proteinuria only by 23 and 25%, respectively, at month 8
(LU-135252, 659 6 53; trandolapril, 645 6 59 mg/day).
During the experimental period the combined therapy had
a marked antiproteinuric effect resulting in a 44%, 39%
and 45% reduction of urinary protein excretion as com-
pared to untreated PHN at months 2, 4 and 8, respectively.
Values of proteinuria in the combined therapy group were
numerically lower than those of each drug alone in most
instances, with a statistically significant difference versus
LU-135252 at four months.
Renal function
Two months after disease induction untreated PHN
animals developed a mild renal insufficiency that worsened
during time, as documented by a progressive increase in
serum creatinine values as compared to control rats (Table
1). LU-135252-treated PHN animals had a similar impaired
renal function. In PHN rats given trandolapril, serum
Fig. 1. Systolic blood pressure measured
during eight months of observation in
untreated PHN rats (;), in PHN animals given
LU-135252 (f), or trandolapril (3), or the
combination of LU-135252 and trandolapril
(M) and controls (p). Data are mean 6 SE.
*P , 0.01 versus control; ‡P , 0.05, #P , 0.01
versus PHN; †P , 0.05 versus PHN1 LU-
135252.
Fig. 2. Time course of urinary protein
excretion in PHN animals receiving no
treatment (;), or LU-135252 (f) or
trandolapril (3) or the combination of LU-
135252 and trandolapril (M) and controls (p).
Data are mean 6 SE. *P , 0.01 versus control;
#P , 0.05 versus PHN; †P , 0.05 versus
PHN1 LU-135252.
Benigni et al: Angiotensin and endothelin blockade in PHN356
creatinine levels were slightly lower than those of untreated
PHN. By contrast, in PHN rats given the combined therapy
the serum creatinine values remained fairly stable through-
out the study, at eight months being significantly lower than
those of untreated PHN rats as well as of PHN rats treated
with LU-135252 or trandolapril.
Renal histology
The results of renal morphology by light microscopy are
reported in Table 2. Untreated PHN rats showed focal and
segmental glomerulosclerosis affecting on average 52.5%
of glomeruli. Tubulointerstitial changes consisted of inter-
stitial fibrosis and inflammation associated with tubular
atrophy and large eosinophilic casts in the tubular lumen
(mean score 2.4). In PHN rats given LU-135252 glomerular
and tubular changes were similar to those of untreated
PHN rats. In rats given trandolapril percentage of glomer-
uli with sclerotic changes averaged 31.6% and score for
tubulointerstitial damage averaged 2.1. By contrast, in PHN
rats treated with the combined therapy glomerular and
tubular structural integrity was better preserved with re-
spect to untreated PHN rats. Thus, sclerotic changes af-
fected on average 19.5% of glomeruli (P , 0.05 vs.
untreated PHN) and the score for tubulointerstitial dam-
age averaged 1.4.
DISCUSSION
The results of the present study offer a rationale for
combining an ACE-inhibitor with an ET receptor antago-
nist in patients who do not respond completely to ACE-
inhibitors.
The present results show that the ACE-inhibitor tran-
dolapril limited tubulointerstitial and glomerular damage.
In the present set of experiments trandolapril was less
effective in reducing urinary proteins and renal injury than
other molecules of the same class studied previously by our
own group in PHN [14, 26]. However, formal comparison
between the present and previous studies performed with
other ACE inhibitors cannot be done, since experiments of
this kind performed in the accelerated model of the PHN
using different ACE inhibitors have never been done. It is
therefore conceivable that the apparent discrepancy be-
tween the present study and previous ones are indeed
explained by the fact that here we have studied a far more
severe disease, obtained by uninephrectomizing animals at
day 7 after disease induction to accelerate renal damage.
Indeed, despite blood pressure levels that were comparable
to the two kidney model, proteinuria was much more severe
considering the animals had only one kidney. As a conse-
quence of increased protein traffic renal damage occurred
earlier. In theory a more severe disease should have
maximized the chances of highlighting relative differences
in the various drug regimens employed. This is of special
interest in the field of progressive nephropathies since in
many experimental models, but not in human renal dis-
eases, ACE-inhibition alone is so powerful as to fully
normalize urinary protein [3, 27–29]. In most models it
entirely protects animals from renal failure and may pro-
long life occasionally exceeding the expected survival rate
of control animals [2, 30]. To start with, findings that the
protective effect of trandolapril in this accelerated model of
PHN was only partial, were instrumental to subsequent
studies planned to verify whether alternative treatments
and/or combination of drugs were more effective than
ACE-inhibition alone. The rationale for using an ET-1
antagonist to retard renal disease progression in our model
rests on data that kidneys from PHN rats synthesize more
ET-1 than normal kidneys [14, 31]. Excessive ET-1 mRNA
and protein were localized in proximal tubules and pre-
ceeded inflammatory cells infiltrating the renal interstitium
and interstitial fibrosis [31]. At variance with trandolapril,
Table 1. Time course of serum creatinine (mg/dl)
Months
0 2 4 8
PHN 0.60 6 0.02 0.92 6 0.03b 0.85 6 0.09b 1.80 6 0.33b
PHN 1 LU-135252 0.64 6 0.01 0.79 6 0.02b 0.91 6 0.02b 1.80 6 0.28b
PHN 1 trandolapril 0.61 6 0.02 0.84 6 0.01b 0.92 6 0.11a 1.40 6 0.19b
PHN 1 LU-135252 1 trand. 0.63 6 0.02 0.82 6 0.02b 0.74 6 0.05a 0.89 6 0.11cd
Control 0.59 6 0.02 0.57 6 0.02 0.61 6 0.03 0.76 6 0.02
Data are mean 6 SE.
a P , 0.05, b P , 0.01 vs. control at corresponding time
c P , 0.01 vs. PHN at corresponding time
d P , 0.05 vs. PHN 1 LU-135252 and PHN 1 trandolapril at corresponding time











PHN 52.5 6 7.8b 2.4 6 0.3b 2.4 6 0.3b
PHN 1 LU-135252 55.3 6 5.3b 2.8 6 0.1b 2.8 6 0.1b
PHN 1 trandolapril 31.6 6 7.1bd 2.1 6 0.3b 2.1 6 0.3b
PHN 1 LU-135252 1 trandolapril 19.5 6 7.6ace 1.4 6 0.1d 1.4 6 0.1d
Control 0.8 6 0.8 0.3 6 0.2 0.3 6 0.2
Data are mean 6 SE.
a P , 0.05, b P , 0.01 vs. control, c P , 0.05 vs. PHN,
d P , 0.05, e P , 0.01 vs. PHN 1 LU-135252
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the endothelin antagonist LU-135252 given daily as a single
agent did not prevent proteinuria, renal function impair-
ment and renal structural damage, despite the fact that it
maintained systolic blood pressure within normal values.
Lack of efficacy of the ET-receptor antagonist alone in
this accelerated model of PHN would indicate that–at least
at an early stage of the disease–the major mediator of renal
damage is rather Ang II, than ET-1. If anything, one can
speculate that ET-1 may contribute to amplify the damage
conceivably in a relatively advanced stage of the disease
[32]. This possibility is consistent with findings that exces-
sive ET-1 is formed in the kidney not sooner than eight
months after the induction of the disease in PHN, as
documented by a previous study of our group [14]. To test
formally the hypothesis that following a prolonged enough
period of heavy proteinuria ET-1 does play a contributory
role in the subsequent renal structural damage, possibly
favoring interstitial inflammation and fibrosis, we used both
trandolapril and the endothelin antagonist LU-135252 in
combination. The effect of combining trandolapril with
LU-135252 was accompanied by a reduction in proteinuria
that reached significantly different values as compared to
PHN alone at all time points examined in the course of the
study. At variance, neither trandolapril nor LU-135252
given alone, despite numerically reducing proteinuria at all
time points examined, did so to an extent that reached
statistically significance. The preventive effect of such a
treatment regimen as compared to each molecule alone
against deterioration in renal function and structural dam-
age was even more remarkable.
The results of this study confirmed the major effect of
inhibiting Ang II in progressive immune nephropathies and
at the same time provided the evidence of the better
renoprotection of a multidrug approach in a model that is
clearly more severe as compared to the ones used so far in
similar studies. These findings can in some way be recon-
ciled with previous experimental and human data, which
collectively indicated that the process of renal disease
progression was linked to the local formation of Ang II,
whose effect of enhancing glomerular hydraulic pressure
[33] has been considered instrumental to initial injury. In
turn, elevation of glomerular capillary pressure impairs
glomerular permselectivity and promotes a complex inter-
play of events recapitulated by an increased expression of
vasoactive and inflammatory molecules in proximal tubular
cells activated by protein overload [5, 6]. Of these, up-
regulation of ET-1 gene expression and enhanced synthesis
of the corresponding protein were constant findings of in
vitro and in vivo experiments performed thus far. Given the
fact that Ang II and ET-1 both promote extracellular
matrix accumulation in various renal cells, one may specu-
late that both contribute to the process of renal scarring. As
for the relative role of enhanced renal ET-1 in progressive
renal injury, the subject has been considerably advanced by
evidence that renal overexpression of human ET-1 gene in
transgenic mice gave severe tubulointerstitial and glomer-
ular injury, ending with reduced GFR [34].
The above findings help to explain the additive renopro-
tective effect of simultaneously blocking Ang II and endo-
thelin in our accelerated model of PHN, and support the
notion that renal disease progresses by an interaction of
different mechanism(s) of which at least two have been
identified here as suitable to pharmacological modulation.
In addition to ACE-inhibitors, drugs that limit the conse-
quences of protein traffic and reabsorption can theoreti-
cally be used in the future as part of the therapeutic
armamentarium to cure progressive nephropathies. ET-1
antagonists are probably the first example of this kind.
Results of experimental studies in the near future will
identify many more factors involved in tubulointerstitial
and glomerular damage triggered by protein traffic. A
multidrug approach targeting these molecules will probably
be the way to limit and hopefully avoid renal failure in this
setting. Even now those patients whose disease responds
only partially to ACE-inhibitors are candidates to try an
endothelin antagonist in addition, within the context of
controlled clinical designs.
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